API | bimagrumab

bimagrumab Report issue

Biologics mAb Experimental

AACT ChEMBL DrugBank MeSH

Active Ingredient History

NOW

Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. On August 20, 2013, it was announced that bimagrumab had received a breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by the US Food and Drug Administration. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
bimagrumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Activin receptor type-2B (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

bimagrumab | bym338

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (9)

Approved Indications (1)

Myositis, Inclusion Body

Experimental Indications - Clinical Trial Phases 1-4 (9)

Cachexia (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Hip Fractures (Phase 2)

Muscle, Skeletal (Phase 2)

Myositis (Phase 2/Phase 3)

Myositis, Inclusion Body (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Respiration, Artificial (Phase 2)

Sarcopenia (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 13
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue